ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's potential. See more here.

Similar to Bacillus Calmette-Guérin (BCG) therapy used for bladder cancer, ICVB-1042 is designed to train the immune system on tumors but with a cancer-specific response and a robust immune reaction.

Rising temperature and growing threat of climate change may increase default risk in 30 per cent of agri and housing loans portfolio in the next five years, according to an analysis by BCG.

Malmström and colleagues 7 collected individual patient data from previous trials of BCG versus mitomycin C and performed a meta-analysis on 2,820 such data sets. After a median follow-up of 4.4 ...

Rising temperature and growing threat of climate change may increase default risk in 30 per cent of agri and housing loans portfolio in the next five years, according to an analysis by BCG.

Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

A new report released today, January 22, from Nasdaq and Boston Consulting Group (BCG), suggests that by embracing ... risk management, oversight, analysis, and innovation. The report advocates ...